Abstract
Recent surveillance from US hospitals shows that more than 99.5% of vancomycin-resistant enterococci (VRE) isolates remain susceptible to daptomycin. This report describes emergence of daptomycin-resistant VRE at a major cancer center. The percentage of patients with daptomycin-resistant VRE bacteremia increased from 3.4% in 2007 to 15.2% in 2009 ([Formula: see text]). Without susceptibility data, empiric daptomycin therapy for VRE infections should be used with caution.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Anti-Bacterial Agents / therapeutic use*
-
Bacteremia / complications
-
Bacteremia / drug therapy
-
Child
-
Daptomycin / therapeutic use*
-
Drug Resistance, Multiple, Bacterial*
-
Enterococcus faecium / drug effects*
-
Enterococcus faecium / isolation & purification
-
Female
-
Gram-Positive Bacterial Infections / complications
-
Gram-Positive Bacterial Infections / drug therapy*
-
Gram-Positive Bacterial Infections / microbiology
-
Humans
-
Male
-
Microbial Sensitivity Tests
-
Middle Aged
-
Neoplasms / complications
-
Vancomycin Resistance
Substances
-
Anti-Bacterial Agents
-
Daptomycin